The assessment of serum hepatitis C virus RNA 12 weeks after the end of treatment using TaqMan polymerase chain reaction is less relevant than after 24 weeks for predicting sustained virological response

Hepatology

Volumn 54, Issue 4, 2011, Pages 1482-1482

  Kanda, Tatsuo ^a   Imazeki, Fumio ^a   Wu, Shuang ^a   Nakamoto, Shingo ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIMIT OF DETECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SERUM; TAQMAN POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 80053304454     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24512     Document Type: Letter

References (6)

1. Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. HEPATOLOGY 2010; 51: 1122-1126.
2. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010; 4: 548-561.
3. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. HEPATOLOGY 2009; 49: 729-738.
4. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. HEPATOLOGY 2010; 52: 833-844.
5. Kanda T, Imazeki F, Yonemitsu Y, Mikami S, Takada N, Nishino T, et al. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test. J Viral Hepat 2011; 18: e292-e297.
6. Kanda T, Imazeki F, Mikami S, Kato K, Shimada N, Yonemitsu Y, et al. Ocurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients. Oncology 2010 (in press).